Sivik Global Healthcare LLC Has $5.78 Million Stock Position in Danaher Co. (NYSE:DHR)

Sivik Global Healthcare LLC lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 9.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,000 shares of the conglomerate’s stock after selling 2,500 shares during the quarter. Danaher accounts for approximately 2.4% of Sivik Global Healthcare LLC’s holdings, making the stock its 21st largest holding. Sivik Global Healthcare LLC’s holdings in Danaher were worth $5,784,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. BKM Wealth Management LLC bought a new stake in Danaher during the 4th quarter worth approximately $27,000. Wetzel Investment Advisors Inc. bought a new stake in shares of Danaher during the fourth quarter worth $29,000. OFI Invest Asset Management acquired a new stake in shares of Danaher during the third quarter worth $30,000. Rakuten Securities Inc. bought a new stake in Danaher in the 4th quarter valued at $36,000. Finally, Financial Connections Group Inc. acquired a new position in Danaher in the 4th quarter worth $41,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Insiders have sold 106,565 shares of company stock valued at $26,641,364 over the last ninety days. 10.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DHR. HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their price target for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Citigroup lifted their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Barclays upped their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. KeyCorp lifted their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $269.64.

Danaher Stock Performance

Shares of Danaher stock traded down $0.16 during trading on Tuesday, hitting $246.66. 3,940,969 shares of the stock were exchanged, compared to its average volume of 2,785,271. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The stock has a market capitalization of $182.70 billion, a price-to-earnings ratio of 41.81, a price-to-earnings-growth ratio of 3.80 and a beta of 0.83. The company has a fifty day moving average price of $248.78 and a 200-day moving average price of $231.79. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the previous year, the business earned $2.36 earnings per share. The business’s revenue was down 2.6% compared to the same quarter last year. As a group, equities analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were issued a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date was Wednesday, March 27th. Danaher’s payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.